Abstract
The paucity of information on the presence of the dopamine transporter (DAT) in blood cells, prompted us to explore it in human resting lymphocytes by means of the binding of 3H-WIN 35,428, a compound which is currently considered the most selective ligand for labelling this protein, and by means of the specific reuptake of 3H-dopamine (3H-DA). Lymphocytes were obtained by 15 healthy subjects. The results showed the presence of a specific and saturable binding of 3H-WIN 35,428, which labelled one site only. A specific 3H-DA reuptake was also measured. The pharmacological characterization of both binding and reuptake was overlapping. These findings would indicate that human resting lymphocytes carry the DAT, whose functions in periphery are still unknown.
Similar content being viewed by others
References
Cragg SJ, Rice ME (2004) DAncing past the DAT at a DA synapse. Trends Neurosci 27(5):270–277
Amara SG, Kuhar MJ (1993) Neurotransmitter transporters: recent progress. Annu Rev Neurosci 16:73–93
Giros B, el Mestikawy S, Bertrand L, Caron MG (1991) Cloning and functional characterization of a cocaine-sensitive dopamine transporter. FEBS Lett 295(1–3):149–154
Pristupa ZB, McConkey F, Liu F, Man HY, Lee FJ, Wang YT, Niznik HB (1998) Protein kinase-mediated bidirectional trafficking and functional regulation of the human dopamine transporter. Synapse 30(1):79–87
Little KY, Carroll FI, Cassin BJ (1995) Characterization and localization of [125I]RTI-121 binding sites in human striatum and medial temporal lobe. J Pharmacol Exp Ther 274(3):1473–1483
Boja JW, Carroll FI, Vaughan RA, Kopajtic T, Kuhar MJ (1998) Multiple binding sites for [125I]RTI-121 and other cocaine analogs in rat frontal cerebral cortex. Synapse 30(1):9–17
Ciliax BJ, Drash GW, Staley JK, Haber S, Mobley CJ, Miller GW, Mufson EJ, Mash DC, Levey AI (1999) Immunocytochemical localization of the dopamine transporter in human brain. J Comp Neurol 409(1):38–56
Marazziti D, Baroni S, Fabbrini L, Italiani P, Catena M, Dell’Osso B, Betti L, Giannaccini G, Lucacchini A, Cassano GB (2006) Binding of 3H-WIN-35, 428 and 125I-RTI-121 to human platelet membranes. Neurochem Res 31(3):361–365
Frankhauser P, Grimmer Y, Bugert P, Deuschle M, Schmidt M, Schloss P (2006) Characterization of the neuronal dopamine transporter DAT in human blood platelets. Neurosci Lett 399(3):197–201
Lingjaerde O, Kildemo O (1981) Dopamine uptake in platelets: two different low-affinity, saturable mechanisms. Agents Actions 11(4):410–416
Sundram S, Dean B, Copolov DL (1994) The development of a method to measure [3H] dopamine uptake by washed platelets provides no evidence for circulating inhibitors of platelet dopamine uptake in schizophrenia. Biol Psychiatry 36(9):595–600
Lingjaerde O (1995) Dopamine uptake in platelets. Biol Psychiatry 38(6):416–417
Rotman A, Munitz H, Modai I, Tjano S, Wijsenbeek H (1980) A comparative uptake study of serotonin, dopamine, and norepinephrine by platelets of acute schizophrenic patients. Psychiatry Res 3(3):239–246
Rabey JM, Lerner A, Sigal M, Graff E, Oberman Z (1992) [3H]dopamine uptake by platelet storage granules in schizophrenia. Life Sci 50(1):65–72
Dean B, Sundram S, Hill C, Copolov DL (1996) Platelet [3H]dopamine uptake is differentially affected by neuroleptic drug treatment in schizophrenia and schizophreniform disorder. Prog Neuropsychopharmacol Biol Psychiatry 20(1):45–55
Takahashi N, Nagai Y, Ueno S, Saeki Y, Yanigihara T (1992) Human peripheral blood lymphocytes express D5 dopamine receptor gene and transcribe the two pseudo genes. FEBS Lett 314:23–25
Nagai Y, Ueno S, Saeki Y, Soga F, Yanagihara T (1993) Expression of D3 dopamine receptor gene and novel variant transcript generated by alternative splicing in human peripheral blood lymphocytes. Biochem Biophys Res Commun 194:368–374
Vile JM, Strange PG (1995) High-affinity binding sites for neuroleptic drugs in human peripheral blood lymphocytes and their relation to dopamine receptors. Biochem Pharmacol 49:747–753
Bondy B, De Jonge S, Pander S, Primbs J, Ackenheil M (1996) Identification of dopamine D4 mRNA in circulating lymphocytes using nested polymerase chain reaction. J Neuroimmunol 71:139–144
Josefsson E, Bergquist J, Ekman R, Tarkowski A (1996) Catecholamines are synthesized by mouse lymphocytes and regulate function of these cells by induction of apoptosis. Immunology 82:73–80
Musso NR, Brenci S, Setti M, Indiveri F, Lotti G (1996) Catecholamine content and in vitro catecholamine synthesis in peripheral human lymphocytes. J Clin Endocrinol Metab 81:3553–3557
Bergquist J, Silberring J (1998) Identification of catecholamines in the immune system by electrospray ionisation mass spectrometry. Commun Mass Spectrom 12:683–688
Caronti B, Tanda G, Colosino C, Ruggeri S, Calderaro C, Paladini G, Pontieri FE, Di Chiara G (1999) Reduced dopamine in peripheral blood lymphocytes in Parkinson’s disease. Neuroreport 10:2907–2910
Tsao CW, Lin YS, Cheng JT (1998) Inhibition of immune cell proliferation with haloperidol and relationship of tyrosine hydroxylase expression to immune cell growth. Life Sci 62:335–344
Faraj BA, Olkowski ZL, Jackson RT (1995) A cocaine-sensitive active dopamine transport in human lymphocytes. Biochem Pharmacol 50:1007–1014
Krieger K, Klimke A, Henning U (1998) Active 3H-dopamine uptake displayed by native lymphocyte suspension is mainly due to contaminating platelets. Pharmacopsychiatry 31:193–198
Amenta F, Bronzetti E, Cantalamessa F, El-Assouad D, Felici L, Ricci A, Tayebati SK (2001) Identification of dopamine plasma membrane and vesicular transporters in human peripheral blood lymphocytes. J Neuroimmunol 117(1–2):133–142
Caronti B, Antonini G, Calderaro C, Ruggieri S, Palladini G, Pontieri FE, Colosimo C (2001) Dopamine transporter immunoreactivity in peripheral blood lymphocytes in Parkinson’s disease. J Neural Transm 108(7):803–807
Mill J, Asherson P, Browes C, D’Souza U, Craig I (2002) Expression of the dopamine transporter gene is regulated by the 3′ UTR VNTR: evidence from brain and lymphocytes using quantitative RT-PCR. Am J Med Genet 114(8):975–979
Marazziti D, Rossi A, Giannaccini G, Baroni S, Lucacchini A, Cassano GB (1998) Presence and characterization of the serotonin transporter in human resting lymphocytes. Neuropsychopharmacology 19(2):154–159
McPherson GA (1985) Kinetic, EBDA, LIGAND, Lowry: a collection of radioligand binding analysis programs. Cambridge, Biosoft
Carroll FI, Kotian P, Dehghani A, Gray JL, Kuzemko MA, Parham KA, Abraham P, Lewin AH, Boja JW, Kuhar MJ (1995) Cocaine and 3 beta-(4′-substituted phenyl)tropane-2 beta-carboxylic acid ester and amide analogues. New high-affinity and selective compounds for the dopamine transporter. J Med Chem 38(2):379–388
Ukairo OT, Bondi CD, Newman AH, Kulkarni SS, Kozikowski AP, Pan S, Surratt CK (2005) Recognition of benztropine by the dopamine transporter (DAT) differs from that of the classical dopamine uptake inhibitors cocaine, methylphenidate, and mazindol as a function of a DAT transmembrane 1 aspartic acid residue. J Pharmacol Exp Ther 314(2):575–583
Buttarelli FR, Circella A, Pellicano C, Pontieri FE (2006) Dopamine transporter immunoreactivity in peripheral blood mononuclear cells in amyotrophic lateral sclerosis. Eur J Neurol 13(4):416–418
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Marazziti, D., Baroni, S., Catena Dell’Osso, M. et al. Presence and Characterization of the Dopamine Transporter in Human Resting Lymphocytes. Neurochem Res 33, 1011–1016 (2008). https://doi.org/10.1007/s11064-007-9541-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11064-007-9541-4